8-K: Halozyme Appoints David Ramsay as Interim CFO

Halozyme Therapeutics, Inc. announced the appointment of David Ramsay, a former CFO, as its Interim Chief Financial Officer, effective March 23, 2026.

Summary

• Halozyme Therapeutics, Inc. appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026.
• Mr. Ramsay previously served as Halozyme's CFO from 2003 to 2009 and again from 2013 to 2015, and as VP, Corporate Development from 2009 to 2013.
• He will receive a monthly salary of $50,000 and an equity grant of 10,000 restricted stock units (RSUs) vesting June 30, 2026, with an additional 2,500 RSUs if he continues past July 1, 2026.
• The company is actively searching for a permanent CFO with the help of a leading executive search firm.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive and stable interim appointment given Mr. Ramsay's extensive prior experience with Halozyme and strong industry background, mitigating immediate leadership uncertainty. The interim nature and ongoing search for a permanent CFO introduce a minor element of uncertainty, but the overall sentiment is favorable due to the quality of the interim choice.

Positives

• Appointment of an experienced individual, David Ramsay, who has previously served as Halozyme's CFO and VP of Corporate Development.
• Mr. Ramsay brings over 30 years of strategic financial leadership, capital markets expertise, and investor relations experience in the biotechnology and life sciences sectors.
• His prior tenure saw the company evolve from a private enterprise to a billion-dollar public biopharmaceutical company, establishing foundational financial and technology commercialization infrastructure.
• The company's CEO, Dr. Helen Torley, expressed strong confidence in Mr. Ramsay's capabilities and deep understanding of Halozyme.

Negatives

• The appointment is on an interim basis, indicating a temporary solution while a permanent CFO is sought.
• The company faces the ongoing task of finding a suitable permanent CFO, which could introduce uncertainty.

Risks

• Potential delays in hiring a permanent chief financial officer.

Future Outlook

The company is actively conducting an executive search for a permanent Chief Financial Officer, engaging a leading executive search firm to identify candidates with capital markets expertise and strategic capabilities. Mr. Ramsay will remain in the interim role until a permanent CFO is appointed.

Management Comments

• "I am thrilled to have the opportunity to work with David again." Dr. Helen Torley, President and Chief Executive Officer.
• "His deep understanding of Halozyme, combined with his exceptional capital markets expertise, investor expertise and credibility, and his longstanding record of financial leadership, makes him an invaluable partner as we advance our strategic priorities." Dr. Helen Torley.
• "David has made a lasting impact on Halozyme’s evolution, and we are fortunate to welcome him back into a role where his experience and leadership will be immediately impactful." Dr. Helen Torley.

Industry Context

StockSavvy.ai notes that the appointment of an interim CFO with prior company experience is a common strategy in the biopharmaceutical sector to ensure continuity and stability during a leadership transition, especially for companies with complex drug delivery technologies like Halozyme's ENHANZE, Hypercon, and Surf Bios platforms. This move allows the company to maintain financial oversight while conducting a thorough search for a permanent executive in a competitive talent market.

Management Changes

Stakeholder Impact

• Shareholders: Provides stability in financial leadership during a transition period, potentially reassuring investors. The compensation package for the interim CFO is disclosed.
• Employees: Ensures continuity in financial operations and leadership.
• Customers/Suppliers: Unlikely to have a direct immediate impact.
• Creditors: Maintains financial oversight, which is generally positive for creditor confidence.

Next Steps

• Continue the active executive search for a permanent Chief Financial Officer.
• Mr. Ramsay will oversee financial operations until a permanent CFO is appointed.
• Grant of additional 2,500 RSUs to Mr. Ramsay if he continues as Interim CFO on July 1, 2026.

Key Dates

Recommendation

The appointment of David Ramsay as Interim CFO is a prudent and stabilizing move, leveraging his deep institutional knowledge and extensive industry experience. While his return provides continuity and strong financial leadership during the search for a permanent CFO, it is an interim solution. The filing does not introduce new strategic initiatives or financial performance updates that would warrant a change in investment stance. Investors should hold, awaiting the appointment of a permanent CFO and further operational or financial updates.

Keywords

Halozyme Therapeutics, HALO, Interim CFO, Chief Financial Officer, David Ramsay, biotechnology, life sciences, corporate finance, investor relations, management change, ENHANZE, Hypercon, biopharmaceutical